FDA
-
-
-
-
-
-
-
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
-
-
-
-
-
-
-
Amarin and HLS to present cardiovascular data at Canadian congress
-
-
-
-
-
-
-
Amarin (AMRN) Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA in Europe
-
-
-
-
-
-
-
Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action
-
-
-
-
-
-
-
Amarin Corp. (AMRN): Latest Research Highlighting VASCEPA/VAZKEPA REDUCE-IT Subgroup Data Presented at ESC
-
-
-
-
-
-
-
Amarin Reports First Quarter 2024 Business Update and Financial Results
-
-
-
-
-
-
-
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

